(Q45267389)

English

Low trough plasma concentrations of nevirapine associated with virologic rebounds in HIV-infected patients who switched from protease inhibitors

scientific article published on 15 February 2005

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Low trough plasma concentrations of nevirapine associated with virologic rebounds in HIV-infected patients who switched from protease inhibitors (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

0 references

1 reference

based on heuristic

inferred from title

Gilles Peytavin

3

object named as

Gilles Peytavin

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

author name string

Michel Duong

1

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Marielle Buisson

2

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Evelyne Kohli

4

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Lionel Piroth

5

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Benoit Martha

6

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Michèle Grappin

7

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Pascal Chavanet

8

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Henri Portier

9

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

language of work or name

0 references

publication date

15 February 2005

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Annals of Pharmacotherapy

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

39

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

603-609

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1E563

21 January 2018

Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1E563

21 January 2018

HIV-1 protease inhibitors induce an increase of triglyceride level in HIV-infected men without modification of insulin sensitivity: a longitudinal study.

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1E563

21 January 2018

Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1E563

21 January 2018

Virological, immunological, and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patients with human immunodeficiency virus infection and long-lasting viral suppression

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1E563

21 January 2018

Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with hiv-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled study.

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1E563

21 January 2018

Mechanism of virologic failure after substitution of a protease inhibitor by nevirapine in patients with suppressed plasma HIV-1 RNA.

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1E563

21 January 2018

Defining the toxicity profile of nevirapine and other antiretroviral drugs

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1E563

21 January 2018

High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1E563

21 January 2018

Liver toxicity caused by nevirapine

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1E563

21 January 2018

HIV resistance to nevirapine and other non-nucleoside reverse transcriptase inhibitors

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1E563

21 January 2018

Long-term efficacy and safety of protease inhibitor switching to nevirapine in HIV-infected patients with undetectable virus load

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1E563

21 January 2018

High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1E563

21 January 2018

Low nevirapine plasma concentrations predict virological failure in an unselected HIV-1-infected population

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1E563

21 January 2018

Low risk of treatment failure after substitution of nevirapine for protease inhibitors among human immunodeficiency virus-infected patients with virus suppression

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1E563

21 January 2018

Does an increase in nevirapine plasma levels cause complete virologic suppression in patients experiencing early virologic failure?

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1E563

21 January 2018

Identifiers

10.1345/APH.1E563

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45267389&oldid=2072215130"